CME : 1
Main Results and Clinical Implications of the X:BOT Trial: XR-Naltrexone vs. Buprenorphine-Naloxone Film is organized by American Psychiatric Association (APA). This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credit™.
Release Date:- Jul 31, 2018.
Expiration Date:- Jul 31, 2021.
Physicians who have a waiver to treat opioid use disorder in an office-based setting and other interested clinicians
There is nearly a half century of overwhelming evidence that agonist substitution, initially with methadone and more recently with buprenorphine and naltrexone, is both efficacious in clinical trials and effective in the community in promoting and sustaining abstinence and reducing risks associated with opioid dependence
This webinar will examine the largest such evaluation to date of extended-release naltrexone (XR-NTX) opioid treatment compared to a gold standard of care, buprenorphine maintenance, and discuss the relevance of the data to clinical practice.
• Describe the aims and methods of the X:BOT trial.
• Compare XR-NTX vs. BUP-NX effects on relapse-free survival, opioid use rates, and overdose events.
Additional details will be posted as soon as information is available.
- 60 Minutes
- 30 Minutes
Browse Online CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine